Xeloda® plus Taxol® Effective as Initial Therapy in Metastatic Breast Cancer
According to an article recently published in the Journal of Clinical Oncology, the chemotherapy combination including Xeloda® (capecitabine) and Taxol® is effective as initial therapy in patients with metastatic breast cancer.
Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body. Standard treatment for metastatic breast cancer often includes chemotherapy, which is aimed at improving survival time without diminishing quality of life. Researchers continue to evaluate several chemotherapy regimens and schedules in order to provide optimal outcomes for patients with this disease.
Researchers from Texas and North Carolina recently conducted a clinical trial to evaluate the combination of Xeloda and Taxol as initial therapy in patients with metastatic breast cancer. This trial included 55 patients who received oral Xeloda and weekly Taxol.
- Clinical benefit (anticancer responses or disease stabilization) was achieved in 65% of patients.
- Half of the patients were still responding to therapy at 10 months.
- The most common severe side effects were redness, blistering, or pain on the palms of the hands or soles of the feet, low levels of immune cells, and fatigue.
The researchers concluded that Xeloda plus Taxol is an effective, well-tolerated, and fairly convenient treatment combination as initial therapy for women with metastatic breast cancer.
Women with metastatic breast cancer may wish to speak with their physician regarding their individual risks and benefits of participation in a clinical trial further evaluating Xeloda/Taxol or other promising therapeutic options. Two sources of information regarding ongoing clinical trials include the National Cancer Institute (www.cancer.gov) and www.cancerconsultants.com.
Reference: Blum J, Dees E, Chacko A, et al. Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology. 2006;24:4384-4390.
Copyright © 2018 CancerConnect. All Rights Reserved.